In a recent post on the IVI-sponsored Health Affairs featured blog series, IVI’s Executive Director, Darius Lakdawalla, along with Rachel Sachs and Nicholas Bagley, examine how Medicaid’s best-price rule complicates the development of value-based pricing and suggest a potential solution that could come out of the new Trump administration CMS policies.
Read the full article here.
About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.